Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ...

Multiple myeloma starts in the plasma cells inside your bone marrow. People with multiple myeloma have high levels of certain ...

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

Larson and Tomlinson, 4 in investigating the relation between alterations in serum protein concentrations and antibody production, included 4 patients with multiple myeloma in the group of 12 ...

The modified cells recognise and bind to B-cell maturation antigen (BCMA), a protein that is nearly universally expressed on cancer cells in multiple myeloma, leading to the death of cells ...

Talquetamab (anti–G protein–coupled receptor family C group ... of triple-class–exposed relapsed or refractory multiple myeloma. A total of 94 patients received treatment, with the ...

Response of myeloma to treatment was defined as ≥ 50% decrease of myeloma protein in the serum and ≥ 90% reduction of Bence-Jones proteinuria. Differences among various groups were compared ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients.

leading to the overproduction of abnormal proteins that can cause damage to bones, kidneys, and the immune system. 2 Today, treatment for multiple myeloma often involves an intensive combination ...

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher incidence of grade 3 or 4 infections than with ...